COPD exacerbation

This paper presents current issues with the oral thirdgeneration cephalosporins in outpatient clinical practice. These data are based on the principles of appropriate antimicrobial therapy, national antimicrobial susceptibility data, and …

Gemifloxacin is a new respiratory fluoroquinolone that was approved as Factive® in Russian Federation in December 2005. Among the fluoroquinolones this agent is the most active against Streptococcus pneumoniae, and has similar to other respiratory …